Table 2 . Risk factor comparison between patients with or without liver enzyme elevation.
| Patients with abnormal LFTs (SD) | Patients with normal LFTs (SD) | p -value | |
| Age (years) | 46.1 (13.1) | 46.4 (12.4) | 0.89 |
| BMI (kg/m 2 ) | 27.4 (5.1) | 46.9 (4.6) | 0.55 |
| Crcl (cc/min/1.73 m 2 ) | 107 (42.3) | 103.3 (32.4) | 0.45 |
| Duration of treatment with MTX (months) | 59.6 (42.3) | 35.6 (31.0) | <0.001 |
| Interval of LFTs (months) | 4.5 (2.4) | 4.8 (3.3) | 0.34 |
| Total cumulative dose of MTX (mg) | 1707.3 (1231.1) | 1205.7 (1086.9) | <0.001 |
| Mean MTX dose per month (mg/month) | 34.5 (10.4) | 36 (11.5) | 0.78 |